View of Evaluation of the efficacy of bevacizumab in recurrence metastatic ovarian cancer as a second-line and beyond

Return to Article Details Evaluation of the efficacy of bevacizumab in recurrence metastatic ovarian cancer as a second-line and beyond Download Download PDF